{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:20:32Z","timestamp":1791274832202,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":3066,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]},{"name":"A Sister\u2019s Hope\/Pink Ribbon"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1093\/annonc\/mdq624","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T05:49:32Z","timestamp":1291700972000},"page":"1561-1570","source":"Crossref","is-referenced-by-count":161,"title":["An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients"],"prefix":"10.1016","volume":"22","author":[{"given":"M.A.","family":"Vollebergh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.H.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Nederlof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.A.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.H.","family":"van Beers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.E.","family":"Froklage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Schrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"van de Vijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van Tinteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hauptmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rodenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9472","key":"10.1093\/annonc\/mdq624_bb0010","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1093\/annonc\/mdq624_bb0015","first-page":"405","article-title":"Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer","volume":"62","author":"Yap","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"10.1093\/annonc\/mdq624_bb0020","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.1998.16.4.1350","article-title":"Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer","volume":"16","author":"Eisen","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1 Suppl 3","key":"10.1093\/annonc\/mdq624_bb0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0093-7754(01)90190-3","article-title":"The platinum agents: a role in breast cancer treatment?","volume":"28","author":"Crown","year":"2001","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdq624_bb0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CCO.0b013e328324f48b","article-title":"High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?","volume":"21","author":"Nieto","year":"2009","journal-title":"Curr Opin Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdq624_bb0035","first-page":"6221","article-title":"BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis","volume":"63","author":"Quinn","year":"2003","journal-title":"Cancer Res"},{"issue":"29","key":"10.1093\/annonc\/mdq624_bb0040","doi-asserted-by":"crossref","first-page":"12117","DOI":"10.1073\/pnas.0702955104","article-title":"Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer","volume":"104","author":"Rottenberg","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1093\/annonc\/mdq624_bb0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1093\/annonc\/mdq624_bb0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdq624_bb0055","first-page":"266","article-title":"Therapeutic options for triple-negative breast cancers with defective homologous recombination","volume":"1796","author":"Jaspers","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1093\/annonc\/mdq624_bb0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0959-437X(00)00069-1","article-title":"DNA double strand break repair in mammalian cells","volume":"10","author":"Karran","year":"2000","journal-title":"Curr Opin Genet Dev"},{"issue":"3","key":"10.1093\/annonc\/mdq624_bb0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/85798","article-title":"DNA double-strand breaks: signaling, repair and the cancer connection","volume":"27","author":"Khanna","year":"2001","journal-title":"Nat Genet"},{"issue":"3","key":"10.1093\/annonc\/mdq624_bb0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/35056049","article-title":"Chromosomal stability and the DNA double-stranded break connection","volume":"2","author":"van Gent","year":"2001","journal-title":"Nat Rev Genet"},{"issue":"23","key":"10.1093\/annonc\/mdq624_bb0075","first-page":"7110","article-title":"Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors","volume":"62","author":"Wessels","year":"2002","journal-title":"Cancer Res"},{"issue":"17","key":"10.1093\/annonc\/mdq624_bb0080","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1158\/0008-5472.CAN-05-0570","article-title":"Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization","volume":"65","author":"Jonsson","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdq624_bb0085","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/0008-5472.822.65.3","article-title":"Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations","volume":"65","author":"van Beers","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdq624_bb0090","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0117-z","article-title":"Prediction of BRCA1-association in hereditary non-BRCA1\/2 breast carcinomas with array-CGH","volume":"116","author":"Joosse","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1093\/annonc\/mdq624_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa022794","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer","volume":"349","author":"Rodenhuis","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdq624_bb0100","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"Foulkes","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1093\/annonc\/mdq624_bb0105","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdq624_bb0110","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1093\/annonc\/mdq624_bb0115","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.onc.1210014","article-title":"BRCA1 dysfunction in sporadic basal-like breast cancer","volume":"26","author":"Turner","year":"2007","journal-title":"Oncogene"},{"issue":"5","key":"10.1093\/annonc\/mdq624_bb0120","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1200\/JCO.1996.14.5.1473","article-title":"Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer","volume":"14","author":"Rodenhuis","year":"1996","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdq624_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bmt.1703105","article-title":"Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer","volume":"28","author":"Schrama","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1093\/annonc\/mdq624_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.2002.20.1.58","article-title":"Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer","volume":"20","author":"de Gast","year":"2002","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdq624_bb0140","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1093\/annonc\/mdq624_bb0145","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2005.01.112","article-title":"Clinical trial designs for predictive marker validation in cancer treatment trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdq624_bb0150","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.bjc.6602889","article-title":"A multiplex PCR predictor for ACGH success of FFPE samples","volume":"94","author":"van Beers","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdq624_bb0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2407-7-43","article-title":"Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor material","volume":"7","author":"Joosse","year":"2007","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1093\/annonc\/mdq624_bb0165","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJM198811103191902","article-title":"Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer","volume":"319","author":"Van De Vijver","year":"1988","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1093\/annonc\/mdq624_bb0170","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1093\/annonc\/mdq624_bb0175","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and P53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10 Pt 1","key":"10.1093\/annonc\/mdq624_bb0180","first-page":"3606","article-title":"Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers","volume":"9","author":"Palacios","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1093\/annonc\/mdq624_bb0185","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdq624_bb0190","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdq624_bb0195","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.2002.20.2.463","article-title":"Effect of BRCA mutations on the length of survival in epithelial ovarian tumors","volume":"20","author":"Ben David","year":"2002","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdq624_bb0200","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res"},{"issue":"2 Pt 1","key":"10.1093\/annonc\/mdq624_bb0205","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1158\/1078-0432.CCR-06-1842","article-title":"Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy","volume":"13","author":"Diallo-Danebrock","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1093\/annonc\/mdq624_bb0210","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMoa071167","article-title":"HER2 and response to paclitaxel in node-positive breast cancer","volume":"357","author":"Hayes","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdq624_bb0215","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2008.18.1024","article-title":"Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial","volume":"27","author":"Hugh","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9442","key":"10.1093\/annonc\/mdq624_bb0220","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0140-6736(04)17207-3","article-title":"Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer","volume":"364","author":"Crown","year":"2004","journal-title":"Lancet"},{"issue":"12","key":"10.1093\/annonc\/mdq624_bb0225","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1200\/JCO.2004.02.927","article-title":"What is the role of high-dose chemotherapy in the era of targeted therapies?","volume":"22","author":"Hortobagyi","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdq624_bb0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2004.09.014","article-title":"Is high-dose chemotherapy dead?","volume":"41","author":"Rodenhuis","year":"2005","journal-title":"Eur J Cancer"},{"issue":"9737","key":"10.1093\/annonc\/mdq624_bb0235","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1093\/annonc\/mdq624_bb0135","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1073\/pnas.082099299","article-title":"Diagnosis of multiple cancer types by shrunken centroids of gene expression","volume":"99","author":"Tibshirani","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1093\/annonc\/mdq624_bb0160","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/ng1197-341","article-title":"BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients","volume":"17","author":"Petrij-Bosch","year":"1997","journal-title":"Nat Genet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419384303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419384303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/7\/1561\/13785863\/mdq624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T11:31:18Z","timestamp":1685878278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419384303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0923753419384303"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq624","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}